New Hope for Heart Disease Patients: First Enrollment in Global Study of Innovative Treatment in Portugal

Promising Start for PADN Clinical Study

Pulnovo Medical Limited has announced the first two patient enrollments in Portugal for its global clinical study of PADN technology. This technology aims to treat pulmonary hypertension associated with left heart disease.

This significant milestone took place at Centro Hospitalar Universitário de Lisboa Central - Hospital de Santa Marta. Under the guidance of Professor Hang Zhang from Nanjing Medical University, the procedure was successfully performed by Prof. Ruben Ramos' team, marking the beginning of Pulnovo Medical's global deployment of this innovative treatment.

Successful Early Results

Both procedures went smoothly, and the devices proved to be easy to operate, delivering excellent results. The Portuguese medical team praised the safety and efficacy of the PADN technology, which is supported by years of data. Clinical parameters showed promising results.

PADN technology offers a stable energy output and effective surgical results thanks to its comprehensive design and high-precision algorithm control. These early results are giving hope to patients and medical professionals alike.

Global Implications

Professor Ruben Ramos expressed his optimism about the potential of PADN technology. He highlighted that participating in this global study presents a new treatment option for European patients suffering from pulmonary hypertension associated with left heart disease.

Pulnovo Medical's CEO, Jessie Lian, emphasized that the global PADN clinical study is a key project aimed at innovative cardiovascular treatments. The early success in Portugal reflects the treatment's potential and academic significance worldwide.

Future Prospects

Cynthia Chen, Chairlady of Pulnovo Medical, celebrated this milestone, noting that it marks the acceleration of PADN technology's global progress. She pledged that Pulnovo Medical would continue to promote the global application of PADN, benefiting more patients with this innovative treatment.

The study's progress and results will be closely watched by the medical community, as PADN offers a new pathway for treating a challenging condition.